Hence , it was suggested that circulating levels of the so-called tumor M2-pyruvate kinase (Tu M2-PK) could be used as a tumor marker for monitoring systemic therapies of various solid tumors.
Recently , a high validity correlation of the tumor M2 pyruvate kinase (Tu M2-PK) isoenzyme in comparison to standard tumor markers has been demonstrated in solid tumors.
Heterogeneity also existed in isozyme composition of pyruvate kinase.
M-isozyme pyruvate kinase activity proved to be elevated in the liver of rats with hepatoma induced by p-dimethylaminoazobenzene.
To evaluate the in vivo effect of glutamine on cobalt-generated oxidative stress and (HO-1) induction in rat liver.